Elezanumab

Elezanumab
Monoclonal antibody
Type	?
Clinical data
Other names	AE12-1Y-QL; ABT-555
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1791416-49-3;
UNII	SK1LVT23A1;

Elezanumab (development names AE12-1Y-QL and ABT-555) is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke.^[1]^[2]^[3]^[4]

References

^ Huang, Lili; Fung, Emma; Bose, Sahana; Popp, Andreas; Böser, Preethne; Memmott, John; Kutskova, Yuliya A.; Miller, Renee; Tarcsa, Edit; Klein, Corinna; Veldman, Geertruida M.; Mueller, Bernhard K.; Cui, Yi-Fang (November 2021). "Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models". Neurobiology of Disease. 159: 105492. doi:10.1016/j.nbd.2021.105492. PMID 34478849. S2CID 237396110.
^ Kalluri, Hari V.; Rosebraugh, Matthew R.; Misko, Thomas P.; Ziemann, Adam; Liu, Wei; Cree, Bruce A. C. (February 2023). "Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants". Annals of Neurology. 93 (2): 285–296. doi:10.1002/ana.26503. ISSN 0364-5134. PMC 10100020. PMID 36093738.
^ Jacobson, Peer B.; Goody, Robin; Lawrence, Matthew; Mueller, Bernhard K.; Zhang, Xiaomeng; Hooker, Bradley A.; Pfleeger, Kimberly; Ziemann, Adam; Locke, Charles; Barraud, Quentin; Droescher, Mathias; Bernhard, Joerg; Popp, Andreas; Boeser, Preethne; Huang, Lili; Mollon, Jennifer; Mordashova, Yulia; Cui, Yi-Fang; Savaryn, John P.; Grinnell, Christine; Dreher, Ingeborg; Gold, Michael; Courtine, Grégoire; Mothe, Andrea; Tator, Charles H.; Guest, James D. (July 2021). "Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates". Neurobiology of Disease. 155: 105385. doi:10.1016/j.nbd.2021.105385. PMID 33991647. S2CID 234683099.
^ Smith, Elaine; Ford, Andria L; Perez-Sanchez, Soledad; Shuaib, Ashfaq; Schwefel, Brittany; Ziemann, Adam (February 2022). "Abstract TP7: Phase 2a Study Of Elezanumab In Patients With Acute Ischemic Stroke". Stroke. 53 (Suppl_1). doi:10.1161/str.53.suppl_1.TP7. ISSN 0039-2499. S2CID 246602705.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Huang, Lili; Fung, Emma; Bose, Sahana; Popp, Andreas; Böser, Preethne; Memmott, John; Kutskova, Yuliya A.; Miller, Renee; Tarcsa, Edit; Klein, Corinna; Veldman, Geertruida M.; Mueller, Bernhard K.; Cui, Yi-Fang (November 2021). "Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models". Neurobiology of Disease. 159: 105492. doi:10.1016/j.nbd.2021.105492. PMID 34478849. S2CID 237396110.

[2] Kalluri, Hari V.; Rosebraugh, Matthew R.; Misko, Thomas P.; Ziemann, Adam; Liu, Wei; Cree, Bruce A. C. (February 2023). "Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants". Annals of Neurology. 93 (2): 285–296. doi:10.1002/ana.26503. ISSN 0364-5134. PMC 10100020. PMID 36093738.

[3] Jacobson, Peer B.; Goody, Robin; Lawrence, Matthew; Mueller, Bernhard K.; Zhang, Xiaomeng; Hooker, Bradley A.; Pfleeger, Kimberly; Ziemann, Adam; Locke, Charles; Barraud, Quentin; Droescher, Mathias; Bernhard, Joerg; Popp, Andreas; Boeser, Preethne; Huang, Lili; Mollon, Jennifer; Mordashova, Yulia; Cui, Yi-Fang; Savaryn, John P.; Grinnell, Christine; Dreher, Ingeborg; Gold, Michael; Courtine, Grégoire; Mothe, Andrea; Tator, Charles H.; Guest, James D. (July 2021). "Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates". Neurobiology of Disease. 155: 105385. doi:10.1016/j.nbd.2021.105385. PMID 33991647. S2CID 234683099.

[4] Smith, Elaine; Ford, Andria L; Perez-Sanchez, Soledad; Shuaib, Ashfaq; Schwefel, Brittany; Ziemann, Adam (February 2022). "Abstract TP7: Phase 2a Study Of Elezanumab In Patients With Acute Ischemic Stroke". Stroke. 53 (Suppl_1). doi:10.1161/str.53.suppl_1.TP7. ISSN 0039-2499. S2CID 246602705.

[1]

[2]

[3]

[4]